Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients may be included in the study if they meet all of the following criteria:~* Male or non-pregnant female at least 18 years of age~* Patients undergoing percutaneous coronary intervention (PCI):~  1. Stable angina (SA) patients with diagnostic coronary angiography within 90 days prior to randomization demonstrating atherosclerosis~ 2. Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) patients with diagnostic coronary angiography within 72 hours prior to randomization demonstrating atherosclerosis~ 3. ST-segment elevation myocardial infarction (STEMI) patients (diagnostic angiography not required)~* Provide written informed consent~Exclusion Criteria:~Patients will be excluded from the study if any of the following exclusion criteria apply prior to randomization:~* Receipt of any P2Y12 inhibitor at any time in the 7 days preceding randomization~* Eptifibatide and tirofiban usage within 12 hours preceding randomization (most recent dose must have been administered ≥12 hours prior to randomization)~* Abciximab usage within 7 days preceding randomization~* Receipt of fibrinolytic therapy in the 12 hours preceding randomization~* Increased bleeding risk: ischemic stroke within the last year or any previous hemorrhagic stroke; tumor, cerebral arteriovenous malformation, or intracranial aneurysm; recent (\<1 month) trauma or major surgery (including bypass surgery); currently receiving warfarin; active bleeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cangrelor (Type: EXPERIMENTAL): Cangrelor was administered as a 30 µg/kg bolus followed by a 4.0 µg/kg/min cangrelor IV infusion for a minimum of 2 hours or until conclusion of the index procedure, whichever is longer. At the discretion of the treating physician, the infusion could be continued for a total duration of 4 hours.~Following the discontinuation of the cangrelor infusion, 600mg of clopidogrel was administered.
- clopidogrel (Type: ACTIVE_COMPARATOR): Clopidogrel 300 mg or 600 mg administered pre or post PCI. Selection of dose and timing of dose were per investigator discretion.~During the PCI a placebo infusion was given to maintain the blinding of the trial. In addition, placebo capsules were administered at the end of the infusion mimic the 600mg post infusion dose provided in the cangrelor arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).